1000002-35-6

Upstream product

• 33414-48-1 3-hydroxy-p-toluic acid ethyl ester 
• 78-39-7 Triethyl orthoacetate 
• 39635-23-9 3-hydroxy-4-methyl-benzoic acid hydrazide 

Downstream Products

• 1000002-37-8 4-Chloro-3-[2-methyl-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenoxymethyl]-thieno[3,2-c]pyridine-7-carboxylic acid ethyl ester 
• 1000002-93-6 5-[4-(4-methoxy-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-2-methyl-phenol 
• 1118785-81-1 4-chloro-1-methyl-3-[2-methyl-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenoxymethyl]-1H-pyrazolo[3,4-d]pyrimidine 

Relevant academic research and scientific papers

PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES

Disclosed are novel pyrazolo[3,4-d]pyrimidine derivatives that are inhibitors of Raf kinase. These compounds and their pharmaceutically-acceptable salts and esters are anti-proliferative agents useful in the treatment or control of proliferative disorders such as solid tumors, in particular breast tumor, colon tumor, lung tumor, prostate tumor, and melanoma. Also disclosed are a composition and a unit dose formulation comprising such a compound, or a pharmaceutically-acceptable salt or ester thereof, methods for making such compounds, and methods for using such compounds, or their pharmaceutically-acceptable salts or esters, in the treatment of proliferative disorders.

Substituted Thieno[3,2-C]Pyridine-7-Carboxylic Acid Derivatives

There are provided compounds of the formula wherein R1, R2, R3, X, Y, Q, Ring A and Ring B are as described. The compounds exhibit activity as anticancer agents.

Substituted thieno[3,2-C]pyridine carboxylic acid derivatives

There are provided compounds of the formula wherein R1, R2, R3, X, ring A and ring B are as described. The compounds exhibit anticancer properties.